Compare ResMed Inc. (RMD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Sana Biotechnology Inc — how do they compare? ResMed Inc. trades at $196 (market cap $28.81B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: ResMed Inc. is far larger — about 33× Sana Biotechnology Inc's market cap, and ResMed Inc. pays a 1.21% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| RMD | SANA | |
|---|---|---|
Market Cap | $28.81B | $873.84M |
Sector | Health | Health |
52-Week High | $293.73 | $5.92 |
52-Week Low | $182.82 | $2.68 |
Enterprise Value | $27.99B | $848.03M |
Dividend Yield | 1.21% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
